Medtech Valuation Killers: 10 Regulatory & Commercialization Traps to Avoid (Ep. 11 on The Pharmcast)

February 8, 2017 Jim Combs

This week on The Pharmcast, we talk with Dr. Janet Vargo and Minnie Baylor-Henry on medtech valuation killers, and the 10 regulatory and commercialization traps to avoid. Dr. Vargo penned an article on the topic for Med Device Online, and joins us today to share the common ways value can be destroyed.

Dr. Vargo is the former Head of Clinical and Regulatory Affairs for Mentor, LLC, a Johnson & Johnson Company, and she advised on clinical trial design, device and biologics safety analyses, due diligence efforts, and regulatory strategy for new-to-the-world products for the entire Johnson & Johnson Medical Device and Diagnostic sector.

Joining her is Minnie Baylor-Henry, former Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s (J&J) Medical Devices & Diagnostics sector as well. 

After evaluating dozens of innovative new medical device products as executives at Johnson & Johnson, and now with YourEncore, Dr. Vargo and Minnie Baylor-Henry has seen firsthand the common mistakes that small companies make.  In this session, they will outline the regulatory and commercialization pitfalls to avoid that will improve your speed to market, valuation, and interest from large medical devices companies.  

Need assistance bringing your medical device to launch? Click here to see how we can assist you in regards to regulatory affairs.

If you have topics you would like YourEncore to explore on future episodes of The Pharmcast, please email with feedback or suggestions.

The Pharmcast is now available for download on iTunes, Google Play, and Stitcher. If you like what you hear, share it with your friends and write a review or give us a rating on your podcast store. 

Previous Video
[WEBINAR] New Models for Breakthrough Innovation
[WEBINAR] New Models for Breakthrough Innovation

Next Article
The Most Important Question for Innovation Teams: Why Are We Here?
The Most Important Question for Innovation Teams: Why Are We Here?

“If I had an hour to solve a problem, I'd spend 55 minutes thinking about the problem and 5 minu...